Eclipse Regenesis

eclipse regenesis, inc. has developed the first restorative therapy to address pediatric and adult short bowel syndrome (sbs), a malabsorption disorder caused by a lack of functional small intestine. current chronic therapies for sbs include expensive medication and intestinal surgery, which come at a staggering average 5-year cost of $1.6m per patient. via distraction enterogenesis, the eclipse xl1 system is able to harness the body’s own tissue regenerative capabilities to produce new, fully functional intestine in vivo. with over 15 years of scientific research and partnerships with the global sbs clinical thought leaders, our team is passionate about pioneering our restorative therapy to a disorder that today has no cure.